BioSpace News Archive

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted paltusotine Orphan Drug Designation for the treatment of acromegaly.

Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced that it has commenced an underwritten public offering of its common stock.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement with kaléo, a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions, to co-promote XHANCE® (fluticasone propionate) exhalation nasal spray 93 mcg, for the treatment of nasal polyps in patients 18 years or older in the United States.

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced reinitiation of enrollment of its P

OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations, announced today that it has submitted for U.S. patent protection, for the first-ever powder for oral liquid formulation of duloxetine hydrochloride. Offering an important delivery alternative for a drug often used for major depressive and generalized anxiety di

Guardant Health, Inc. announced a strategic collaboration with Janssen Biotech, Inc. to pursue regulatory approval and commercialization of the Guardant360® CDx as a companion diagnostic for amivantamab, an investigational EGFR-MET bispecific antibody being studied in the treatment of non-small cell lung cancer.

Global Blood Therapeutics, Inc. announced that on July 1, 2020, the compensation committee of GBT’s board of directors granted 11 new employees restricted stock units for an aggregate of 27,550 shares of the company’s common stock.

Biotricity Inc. ( OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, today provided guidance on its financial results for the year ended March 31, 2020, announcing that it has experienced increases of approximately 260% in gross annual revenues, year over year, and 113% quarter over quarter. This guidance is being provided in advance of filing audited results within its 10-K, which it anticipates f

Highlights: RECCE ® 327 and New RECCE ® 529 compounds were selected for their unique mechanisms of action against hyper-mutation, as indicated on bacteria and viruses (respectively) Testing program will be conducted by CSIRO & University of Melbourne at the Doherty Institute Therapeutic antiviral treatment focus of RECCE ® 327 and RECCE ® 529 may see added potential benefit against secondary bacterial infections SYDNEY, Australia, July 08, 2020 (GLOBE NEWSWIRE)